carvedilol has been researched along with Cardiac Output, Low in 49 studies
Cardiac Output, Low: A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the benefits of carvedilol in patients with heart failure and depressed ejection fraction (EF) have been elucidated, those in patients with preserved EF are not understood." | 9.11 | Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. ( Fukutomi, T; Itoh, M; Kondo, H; Ogata, M; Shigeyama, J; Sugiura, M; Suzuki, S; Takeda, Y; Yamamoto, K, 2004) |
| "The third generation beta-blocker (carvedilol) is effective in reduction of hypertension, and of mortality and morbidity as a supplement to conventional drugs of heart failure therapies (diuretics, ACE inhibitors), based on randomized controlled trials and retrospective analysis." | 8.83 | [The effectiveness of carvedilol in heart failure]. ( Brodszky, V; Farsang, C; Gulácsi, L; Jermendy, G; Kárpáti, K; Vándorfi, G; Zámolyi, K, 2006) |
| "To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH)." | 7.71 | [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener ( Chazova, IE; Irodova, NL; Kochetov, AG; Krasnikova, TL; Masenko, VP, 2002) |
| "The effect of the beta-blocker, carvedilol, and/or ACEI on ventricular function in patients with muscular dystrophy was studied." | 5.12 | Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. ( Ishigaki, K; Kajimoto, H; Nakanishi, T; Nakazawa, M; Okumura, K; Osawa, M; Saito, K; Tomimatsu, H, 2006) |
| "The purpose of the study was to evaluate the influence of metoprolol succinate and carvedilol on the physical ability (FA) of patients with chronic heart failure (CHF) of different etiologies." | 5.12 | [The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]. ( Andreev, DA; Kalashnikov, VIu; Poltavskaia, MG; Sarkisova, EA; Svet, AV; Syrkin, AL, 2007) |
| "Although the benefits of carvedilol in patients with heart failure and depressed ejection fraction (EF) have been elucidated, those in patients with preserved EF are not understood." | 5.11 | Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. ( Fukutomi, T; Itoh, M; Kondo, H; Ogata, M; Shigeyama, J; Sugiura, M; Suzuki, S; Takeda, Y; Yamamoto, K, 2004) |
| "The third generation beta-blocker (carvedilol) is effective in reduction of hypertension, and of mortality and morbidity as a supplement to conventional drugs of heart failure therapies (diuretics, ACE inhibitors), based on randomized controlled trials and retrospective analysis." | 4.83 | [The effectiveness of carvedilol in heart failure]. ( Brodszky, V; Farsang, C; Gulácsi, L; Jermendy, G; Kárpáti, K; Vándorfi, G; Zámolyi, K, 2006) |
| "To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH)." | 3.71 | [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener ( Chazova, IE; Irodova, NL; Kochetov, AG; Krasnikova, TL; Masenko, VP, 2002) |
| "The CAPRICORN and COPERNICUS studies have confirmed the significance of betablocker treatment with carvedilol for indications which this medication did not yet possess: post-infarction with left ventricular dysfunction with or without clinical signs, and stable severe cardiac insufficiency." | 3.71 | [CAPRICORN and COPERINUS studies]. ( Juillière, Y, 2002) |
| "Patients were randomized in a 1:1:1 ratio to twice-daily dosing with placebo, low-dose carvedilol (0." | 2.73 | Carvedilol for children and adolescents with heart failure: a randomized controlled trial. ( Blume, ED; Boucek, MM; Boucek, RJ; Burr, J; Canter, CE; Dodd, DA; Holubkov, R; Hsu, DT; LaSalle, B; Lukas, MA; Mahony, L; Pahl, E; Rosenthal, DN; Ross, RD; Shaddy, RE; Tani, LY, 2007) |
| "Treatment with carvedilol might be effective for decreasing the oxidative DNA damage." | 2.72 | Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. ( Banba, K; Kimura, H; Kono, Y; Kusano, KF; Matsubara, H; Miura, A; Nagase, S; Nakamura, K; Nishii, N; Ohe, T; Sakuragi, S; Watanabe, A, 2006) |
| "With carvedilol, there was a parallel decline from 4." | 2.69 | Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. ( Buchholz-Varley, C; Charney, RH; Eng, C; Kalman, J; Kukin, ML; Levy, DK; Ocampo, ON, 1999) |
| "Carvedilol was added to the usual therapy of 20 patients; placebo was added to the usual therapy of 10 patients." | 2.69 | Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study). ( Bocchi, EA; Caldas, MA; Chizzola, PR; da Costa, JM; Freitas, HF; Mansur, AJ; Marinho, NV; Meneghetti, C; Ramires, JA, 2000) |
| "Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center studies, but its clinical effects have not been evaluated in large, multicenter trials." | 2.68 | Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. ( Cody, RJ; Colucci, WS; Freeman, I; Goldscher, DA; Gottlieb, SS; Gregory, JJ; Kantrowitz, NE; Kinhal, V; Klapholz, M; Kukin, ML; LeJemtel, TH; Liang, CS; Lukas, MA; Packer, M; Pearle, D; Sackner-Bernstein, JD; Shusterman, NH; Udelson, JE; Young, ST, 1996) |
| "Carvedilol reduced all-cause mortality but had no effects on the Minnesota Living With Heart Failure scale, the distance walked in 9 minutes on a self-powered treadmill, or cardiothoracic index." | 2.68 | Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. ( Bowers, JA; Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Hershberger, R; Holcslaw, TL; Krueger, SK; Lukas, MA; Packer, M; Sackner-Bernstein, JD; Uretsky, BF; Young, ST, 1996) |
| "Carvedilol is a multiple action, non-specific, adrenergic beta-blocker, licensed for the treatment of mild, moderate and severe chronic heart failure." | 2.42 | Use of carvedilol in the treatment of heart failure. ( Coats, A, 2003) |
| "Carvedilol was begun 2 weeks after initiation of pacing and continued for 2 weeks." | 1.34 | Carvedilol restore cardiac calcium release channel structure and function in heart failure. ( Xue, R; Xue, SR; Xue, Y, 2007) |
| "Fifty consecutive patients with dilated cardiomyopathy in NYHA class II-IV with a left ventricular ejection fraction (LVEF) of 35% or below were studied with full polysomnography over one night." | 1.34 | Does beta-blocker treatment influence central sleep apnoea? ( Köhnlein, T; Welte, T, 2007) |
| " Beta-blocker dosages were titrated, and three patients achieved the target beta-blocker dosage established for stage A-C heart failure." | 1.34 | Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. ( Earl, GL; Fitzpatrick, JM; Narula, J; Verbos-Kazanas, MA, 2007) |
| "Carvedilol was started in 3721 patients with CHF (median age 65 years, 60% men)." | 1.34 | Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. ( Lainscak, M; Moullet, C; Schön, N; Tendera, M, 2007) |
| " All centres were provided with carvedilol, metoprolol, and bisoprolol at appropriate doses; the choice of the drug and dosage was left to the responsible clinician." | 1.32 | Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. ( Balli, E; Geraci, E; Gorini, M; Gronda, E; Lucci, D; Maggioni, AP; Opasich, C; Sinagra, G; Tavazzi, L; Tognoni, G, 2003) |
| "Treatment with carvedilol was associated with a significant decrease in the risk of any hospitalization (adjusted odds ratio 0." | 1.31 | Reimbursement claims analysis of outcomes with carvedilol and metoprolol. ( Antell, LA; Chang, LL; Luzier, AB; Roth, DA; Xuan, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (22.45) | 18.2507 |
| 2000's | 38 (77.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Irodova, NL | 1 |
| Krasnikova, TL | 1 |
| Masenko, VP | 1 |
| Kochetov, AG | 1 |
| Chazova, IE | 1 |
| Maltsev, VA | 1 |
| Sabbab, HN | 1 |
| Undrovinas, AI | 1 |
| Arnold, RH | 1 |
| Kotlyar, E | 1 |
| Hayward, C | 1 |
| Keogh, AM | 1 |
| Macdonald, PS | 1 |
| Maggioni, AP | 2 |
| Sinagra, G | 1 |
| Opasich, C | 2 |
| Geraci, E | 1 |
| Gorini, M | 1 |
| Gronda, E | 1 |
| Lucci, D | 2 |
| Tognoni, G | 1 |
| Balli, E | 1 |
| Tavazzi, L | 3 |
| Coats, A | 1 |
| Malfatto, G | 1 |
| Facchini, M | 1 |
| Branzi, G | 1 |
| Riva, B | 1 |
| Sala, L | 1 |
| Perego, GB | 1 |
| Drent, M | 1 |
| Gorgels, AP | 1 |
| Bast, A | 1 |
| Syrkin, AL | 2 |
| Kukes, VG | 1 |
| Poltavskaia, MG | 2 |
| Andreev, DA | 2 |
| Aref'eva, AB | 1 |
| Teplonogova, EV | 1 |
| Konova, IA | 1 |
| Rykova, MS | 1 |
| Bellenger, NG | 1 |
| Rajappan, K | 1 |
| Rahman, SL | 1 |
| Lahiri, A | 1 |
| Raval, U | 1 |
| Webster, J | 1 |
| Murray, GD | 1 |
| Coats, AJ | 1 |
| Cleland, JG | 3 |
| Pennell, DJ | 1 |
| Wang, JK | 1 |
| Cui, CC | 1 |
| Zhang, H | 1 |
| Yao, QH | 1 |
| Yao, XW | 1 |
| Chen, XY | 1 |
| Takeda, Y | 1 |
| Fukutomi, T | 1 |
| Suzuki, S | 1 |
| Yamamoto, K | 1 |
| Ogata, M | 1 |
| Kondo, H | 1 |
| Sugiura, M | 1 |
| Shigeyama, J | 1 |
| Itoh, M | 1 |
| Naccarelli, GV | 1 |
| Bell, DS | 1 |
| Lukas, MA | 4 |
| Holdbrook, FK | 1 |
| Fowler, MB | 4 |
| Boccanelli, A | 1 |
| Cafiero, M | 1 |
| Cirrincione, V | 1 |
| Sindaco, DD | 1 |
| Lenarda, AD | 1 |
| Luzio, SD | 1 |
| Faggiano, P | 1 |
| Frigerio, M | 1 |
| Porcu, M | 1 |
| Pulignano, G | 1 |
| Scherillo, M | 1 |
| Charlesworth, A | 1 |
| Lubsen, J | 1 |
| Swedberg, K | 1 |
| Remme, WJ | 1 |
| Erhardt, L | 1 |
| Di Lenarda, A | 1 |
| Komajda, M | 1 |
| Metra, M | 1 |
| Torp-Pedersen, C | 1 |
| Poole-Wilson, PA | 1 |
| Stevenson, LW | 1 |
| Lewis, E | 1 |
| Wagoner, LE | 1 |
| Starling, RC | 1 |
| O'Connor, CM | 1 |
| Xue, SR | 1 |
| Xue, Y | 1 |
| Xue, R | 1 |
| Kajimoto, H | 1 |
| Ishigaki, K | 1 |
| Okumura, K | 1 |
| Tomimatsu, H | 1 |
| Nakazawa, M | 1 |
| Saito, K | 1 |
| Osawa, M | 1 |
| Nakanishi, T | 1 |
| Kono, Y | 1 |
| Nakamura, K | 1 |
| Kimura, H | 1 |
| Nishii, N | 1 |
| Watanabe, A | 1 |
| Banba, K | 1 |
| Miura, A | 1 |
| Nagase, S | 1 |
| Sakuragi, S | 1 |
| Kusano, KF | 1 |
| Matsubara, H | 1 |
| Ohe, T | 1 |
| Kárpáti, K | 1 |
| Brodszky, V | 1 |
| Farsang, C | 1 |
| Jermendy, G | 1 |
| Vándorfi, G | 1 |
| Zámolyi, K | 1 |
| Gulácsi, L | 1 |
| Köhnlein, T | 1 |
| Welte, T | 1 |
| Mezzani, A | 1 |
| Corrà, U | 1 |
| Giordano, A | 1 |
| Cafagna, M | 1 |
| Adriano, EP | 1 |
| Giannuzzi, P | 1 |
| Mochizuki, M | 1 |
| Yano, M | 1 |
| Oda, T | 1 |
| Tateishi, H | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ikeda, Y | 1 |
| Ohkusa, T | 1 |
| Ikemoto, N | 1 |
| Matsuzaki, M | 1 |
| Earl, GL | 1 |
| Verbos-Kazanas, MA | 1 |
| Fitzpatrick, JM | 1 |
| Narula, J | 1 |
| Lee, T | 1 |
| Svet, AV | 1 |
| Sarkisova, EA | 1 |
| Kalashnikov, VIu | 1 |
| Fox, K | 1 |
| Borer, JS | 1 |
| Camm, AJ | 1 |
| Danchin, N | 1 |
| Ferrari, R | 1 |
| Lopez Sendon, JL | 1 |
| Steg, PG | 1 |
| Tardif, JC | 1 |
| Tendera, M | 2 |
| Lainscak, M | 1 |
| Moullet, C | 1 |
| Schön, N | 1 |
| Shaddy, RE | 1 |
| Boucek, MM | 1 |
| Hsu, DT | 1 |
| Boucek, RJ | 1 |
| Canter, CE | 1 |
| Mahony, L | 1 |
| Ross, RD | 1 |
| Pahl, E | 1 |
| Blume, ED | 1 |
| Dodd, DA | 1 |
| Rosenthal, DN | 1 |
| Burr, J | 1 |
| LaSalle, B | 1 |
| Holubkov, R | 1 |
| Tani, LY | 1 |
| Bloomenthal, R | 1 |
| Chatterjee, K | 1 |
| Packer, M | 2 |
| Colucci, WS | 2 |
| Sackner-Bernstein, JD | 2 |
| Liang, CS | 1 |
| Goldscher, DA | 1 |
| Freeman, I | 1 |
| Kukin, ML | 2 |
| Kinhal, V | 1 |
| Udelson, JE | 1 |
| Klapholz, M | 1 |
| Gottlieb, SS | 1 |
| Pearle, D | 1 |
| Cody, RJ | 1 |
| Gregory, JJ | 1 |
| Kantrowitz, NE | 1 |
| LeJemtel, TH | 1 |
| Young, ST | 2 |
| Shusterman, NH | 1 |
| Bristow, MR | 4 |
| Gilbert, EM | 4 |
| Cohn, JN | 1 |
| Krueger, SK | 1 |
| Hershberger, R | 1 |
| Uretsky, BF | 1 |
| Bowers, JA | 1 |
| Holcslaw, TL | 1 |
| Abraham, WT | 3 |
| Adams, KF | 1 |
| Hershberger, RE | 1 |
| Kubo, SH | 1 |
| Narahara, KA | 1 |
| Ingersoll, H | 1 |
| Krueger, S | 1 |
| Young, S | 1 |
| Shusterman, N | 1 |
| Olsen, S | 1 |
| Hattler, B | 1 |
| White, M | 2 |
| Mealy, P | 1 |
| Larrabee, P | 2 |
| Yoshikawa, T | 1 |
| Hattler, BG | 1 |
| Crisman, TS | 1 |
| Lowes, BD | 1 |
| Robertson, AD | 1 |
| Sharpe, N | 1 |
| Doughty, RN | 1 |
| Kalman, J | 1 |
| Charney, RH | 1 |
| Levy, DK | 1 |
| Buchholz-Varley, C | 1 |
| Ocampo, ON | 1 |
| Eng, C | 1 |
| Cleophas, TJ | 1 |
| van der Meulen, J | 1 |
| van de Luit, L | 1 |
| Zwinderman, AH | 1 |
| Hjalmarson, A | 1 |
| Chizzola, PR | 1 |
| Freitas, HF | 1 |
| Caldas, MA | 1 |
| da Costa, JM | 1 |
| Meneghetti, C | 1 |
| Marinho, NV | 1 |
| Mansur, AJ | 1 |
| Ramires, JA | 1 |
| Bocchi, EA | 1 |
| Martínez Martínez, JA | 1 |
| Luzier, AB | 1 |
| Antell, LA | 1 |
| Chang, LL | 1 |
| Xuan, J | 1 |
| Roth, DA | 1 |
| Juillière, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF 1[NCT04882449] | 300 participants (Anticipated) | Interventional | 2021-07-08 | Active, not recruiting | |||
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction[NCT00052026] | Phase 3 | 161 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Randomized Clinical Trial of Radiofrequency Ablation for Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction for Reduced Healthcare Utilization[NCT04327596] | 2 participants (Actual) | Interventional | 2021-01-25 | Terminated (stopped due to lack of enrollment) | |||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
9 reviews available for carvedilol and Cardiac Output, Low
| Article | Year |
|---|---|
Use of carvedilol in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Humans; P | 2003 |
Antiadrenergic therapy in the control of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Cardi | 2005 |
The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.
Topics: Aged; Blood Glucose; Carbazoles; Cardiac Output, Low; Carvedilol; Diabetes Mellitus; Female; Humans; | 2006 |
Mapping the journey.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Humans; Metoprolol; Propan | 2006 |
Cardiac function and heart failure.
Topics: Adrenergic beta-Antagonists; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Carbazoles; Ca | 2006 |
[The effectiveness of carvedilol in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; Drug | 2006 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Resting heart rate in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca | 2007 |
Beta-blockers in heart failure: potential of carvedilol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Cardiac Output, Low; Carvedilol; C | 1993 |
Left ventricular remodelling and improved long-term outcomes in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Humans; P | 1998 |
17 trials available for carvedilol and Cardiac Output, Low
| Article | Year |
|---|---|
Long-term treatment with the beta-blocker carvedilol restores autonomic tone and responsiveness in patients with moderate heart failure.
Topics: Adrenergic beta-Antagonists; Autonomic Nervous System; Carbazoles; Cardiac Output, Low; Carvedilol; | 2003 |
Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Dou | 2004 |
Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibit | 2004 |
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Diu | 2006 |
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles | 2006 |
Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Cardi | 2006 |
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin].
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; | 2007 |
Carvedilol for children and adolescents with heart failure: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Child; Child, | 2007 |
Effect of beta-blockade on chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Double-Bl | 1996 |
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; | 1996 |
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; | 1996 |
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; | 1996 |
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; | 1996 |
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Cardiac Output, | 1996 |
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Cardiac Output, Low; Carvedilol; Chro | 1996 |
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Cardiac Output, Low; Carvedilol; Chro | 1996 |
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Cardiac Output, Low; Carvedilol; Chro | 1996 |
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Cardiac Output, Low; Carvedilol; Chro | 1996 |
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiac Output, Low; Carvedilol; Electrocardiography | 1996 |
Second- and third-generation beta-blocking drugs in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; | 1997 |
Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disea | 1999 |
Daytime-selective antihypertensive activity of celiprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme | 1999 |
Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; | 2000 |
23 other studies available for carvedilol and Cardiac Output, Low
| Article | Year |
|---|---|
[Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiac Output, Low; Carvedilol; Catecho | 2002 |
Down-regulation of sodium current in chronic heart failure: effect of long-term therapy with carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Cardiac Out | 2002 |
Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Echocardiography; Female; | 2003 |
Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic | 2003 |
Cardiac failure associated with G6PD deficiency.
Topics: Animals; Antioxidants; Carbazoles; Cardiac Output, Low; Carvedilol; Female; Glucosephosphate Dehydro | 2003 |
[Effect of beta-blockers metoprolol CR/XL and carvedilol on left ventricular contractility in patients with chronic low cardiac output].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Drug Admi | 2003 |
Top heart failure drugs compared.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Met | 2003 |
I have been diagnosed with heart failure, and my cardiologist has prescribed a medication called Coreg. What will it do for me?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Pro | 2003 |
Adrenergic receptor antagonist prevents the left ventricle with chronic pressure-overload from electrical remodeling.
Topics: Action Potentials; Adrenergic Antagonists; Animals; Carbazoles; Cardiac Output, Low; Carvedilol; Ele | 2004 |
Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic | 2006 |
Carvedilol restore cardiac calcium release channel structure and function in heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Output, Low; Carvedi | 2007 |
Does beta-blocker treatment influence central sleep apnoea?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; Carvedilol; C | 2007 |
Unreliability of the %VO2 reserve versus %heart rate reserve relationship for aerobic effort relative intensity assessment in chronic heart failure patients on or off beta-blocking therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; Carvedi | 2007 |
Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Cardiac Output, Low; Carvedilol; Dogs; Fr | 2007 |
Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Cardiac Output, | 2007 |
Ask the doctor. Does a low ejection fraction doom me to inactivity?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Cardiotonic Agents; Carvedilol; | 2007 |
Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Carbazoles | 2007 |
Heart failure therapy in evolution.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Output, L | 1996 |
Are all beta-blockers for heart failure the same?
Topics: Adrenergic beta-Antagonists; Antioxidants; Carbazoles; Cardiac Output, Low; Carvedilol; Humans; Meto | 2000 |
[Beta blockers: the end of controversy].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Cause of Death; Clinical T | 2000 |
[Beta-blockers in the treatment of systolic dysfunction after myocardial infarction. Closing the circle?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Output, L | 2001 |
Reimbursement claims analysis of outcomes with carvedilol and metoprolol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Comorbidity; Fees, Pharmac | 2002 |
[CAPRICORN and COPERINUS studies].
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Output, Low; | 2002 |